AU2023281232A1 — Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors
Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2024-10-24 · 2y expired
What this patent protects
The invention relates to prolonged-release injectable compositions for use in a method for treating a disease, disorder or condition sensitive to risperidone or to paliperidone with risperidone in a patient who receives one or more inhibitors of the enzyme CYP2D6 (cytochrome P450…
USPTO Abstract
The invention relates to prolonged-release injectable compositions for use in a method for treating a disease, disorder or condition sensitive to risperidone or to paliperidone with risperidone in a patient who receives one or more inhibitors of the enzyme CYP2D6 (cytochrome P450 2D6). The invention also relates to prolonged-release injectable compositions for use in a method for treating a disease, disorder or condition sensitive to risperidone or to paliperidone with risperidone and for simultaneously treating a disease, disorder or condition sensitive to CYP2D6 enzyme inhibitor in a patient. The invention further relates to prolonged-release injectable compositions containing risperidone and a CYP2D6 enzyme inhibitor, wherein the dose of risperidone does not need to be reduced according to the administered dose of CYP2D6 inhibitor.
Drugs covered by this patent
- Risperdal (risperidone) · Johnson & Johnson (Janssen)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.